Dr. Djaballah has several years of industrial experience in early drug discovery gained over the years in pharma and biotech companies. He has extensive experiences in the areas of fluorescence technology, assay development, automation/robotics, HTS, compound & screening data management, software development & novel technologies. Dr Djaballah has been involved in developing and screening several targets in various therapeutic areas, including antibacterials, antivirals, antifungals, diabetes, CNS, cardiovascular, oncology & inflammation. He is currently the director of the high throughput drug screening core facility at Memorial Sloan Kettering Cancer Centre in New York. He obtained his BSc (Hons.) in biochemistry and biotechnology from the University of Birmingham, and his PhD in biochemistry from the University of Leicester, both in England.
Random RNAi Screening Data Analysis Output: A Call for Standardization across Multiple Technologies
We have developed an analysis strategy referred to as the Bhinder-Djaballah analysis (BDA) method. We introduce the H score as measure of combined duplex activities; we address the off-target effects by performing a comprehensive analysis to eliminate those duplex activities due to their seed sequence similarities to miRNAs and/or 3’UTR sequences. I will present and discuss the BDA method.
Add to Calendar ▼2013-05-09 00:00:002013-05-10 00:00:00Europe/LondonGenomics Research Genomics Research in Boston, MA, USABoston, MA, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com
